- Home
- OLOX vs LYRA Comparison
OLOX vs LYRA Comparison
Compare OLOX & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLOX | LYRA |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | | |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OLOX | LYRA |
|---|---|---|
| Price | $0.89 | $1.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 519.8K | 70.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,628.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $1.21 |
| 52 Week High | $96.00 | $37.50 |
Technical Indicators
Market Signals| Indicator | OLOX | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 31.86 | 33.62 |
| Support Level | $0.89 | $1.21 |
| Resistance Level | $1.15 | $2.05 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 12.09 | 25.93 |
Price Performance
Historical ComparisonAbout OLOX Olenox Industries Inc. Common Stock
Olenox Industries Inc is an industrial holding company focused on acquiring, operating, and scaling businesses that provide engineered solutions across industrial, energy, and infrastructure markets. Through its subsidiaries, it delivers high-quality modular and containerized systems designed for rapid deployment and long-term performance.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.